Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4142W | ISIN: US4268974015 | Ticker-Symbol: 3360
München
25.06.25 | 08:07
0,092 Euro
+15,37 % +0,012
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
HEPION PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
HEPION PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur HEPION PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Successfully Completes Application to the OTCQB141 MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for...
► Artikel lesen
16.06.Hepion Pharmaceuticals appoints Kaouthar Lbiati as interim CEO3
16.06.Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer268MORRISTOWN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTC:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for...
► Artikel lesen
09.06.Hepion Pharmaceuticals, Inc. - 8-K, Current Report2
30.05.Hepion Pharmaceuticals, Inc. - 8-K, Current Report7
HEPION PHARMACEUTICALS Aktie jetzt für 0€ handeln
19.05.Hepion Pharmaceuticals, Inc. - 10-Q, Quarterly Report3
12.05.Hepion Pharmaceuticals to be delisted from Nasdaq3
12.05.Hepion Pharmaceuticals wird von der Nasdaq gestrichen8
12.05.Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq389MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis...
► Artikel lesen
07.05.Hepion Pharmaceuticals schließt Lizenzvertrag für Diagnosetests ab2
07.05.Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC100MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis...
► Artikel lesen
06.05.Hepion Pharmaceuticals, Inc. - 8-K, Current Report2
17.04.Hepion Pharmaceuticals, Inc. - 8-K, Current Report1
08.04.Hepion Pharmaceuticals, Inc. - 10-K, Annual Report20
19.03.Hepion Pharmaceuticals, Inc. - 8-K, Current Report3
14.03.Hepion Pharmaceuticals Announces 1-for-50 Reverse Stock Split To Maintain Nasdaq Listing9
14.03.Hepion Pharmaceuticals announces 1-for-50 reverse stock split5
14.03.Hepion Pharmaceuticals führt Aktienzusammenlegung durch, um NASDAQ-Anforderungen zu erfüllen9
14.03.Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Reverse Stock Split240Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage biopharmaceutical...
► Artikel lesen
04.03.Hepion Pharmaceuticals, Inc. - 8-K, Current Report6
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1